The Freedom Stack

Overview

The Freedom Stack groups three research materials that are each characterized in a separate body of published work. It ships as five individual vials, and the three literatures behind them do not overlap.

GLP3-R is retatrutide (LY3437943). Coskun et al. published its discovery-to-clinical-proof-of-concept characterization as a triple glucagon, GIP, and GLP-1 receptor agonist, and Urva et al. reported the phase 1b multiple-ascending-dose study.[1][2] Phase 2 trials in obesity and in type 2 diabetes have been published in NEJM and The Lancet respectively.[3][4] It remains an investigational compound with no regulatory approval.

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide. Szeto described it as a first-in-class cardiolipin-protective compound, and Birk et al. reported that it re-energizes ischemic mitochondria by interacting with cardiolipin and by targeting the cytochrome c/cardiolipin complex.[5][6][7]

KLOW is itself a four-peptide blend — GHK-Cu, BPC-157, TB-500, and KPV — whose components are characterized in the tissue-repair and inflammation literatures: copper-dependent gene and matrix modulation, VEGFR2-associated angiogenic signalling, G-actin binding, and melanocortin-derived anti-inflammatory activity respectively.[12][15][17][19]

No peer-reviewed study has evaluated these materials together as a stack. Every citation on this page describes a single component studied on its own, and no published work characterizes interactions among incretin-receptor agonism, mitochondrial cardiolipin binding, and tissue-repair peptide signalling. Investigators should treat the kit as three separate research materials and consult the dedicated GLP3-R, SS-31, and KLOW entries for complete mechanism, applications, and reference lists.

Reported Mechanisms — Component by Component

Each section below summarizes the published mechanism of a single component. No combined mechanism is described in the literature, and none is asserted here.

1. GLP3-R / Retatrutide (30 mg, 1 vial) — Triple Receptor Agonism

Retatrutide is described as engaging the GIP, GLP-1, and glucagon receptors with a single peptide sequence — the feature that distinguishes it from dual GIP/GLP-1 agonism and from GLP-1-selective agonism.[1] Clinical pharmacology has been reported in a phase 1b multiple-ascending-dose trial and in phase 2 studies of the pharmaceutical formulation.[2][3][4]

2. SS-31 / Elamipretide (100 mg across 2 vials) — Cardiolipin Interaction

SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin, the signature phospholipid of that membrane. Birk et al. reported that this interaction re-energizes ischemic mitochondria and that targeting the cytochrome c/cardiolipin complex promotes electron transport and mitochondrial ATP synthesis.[6][7] Campbell et al. reported effects on age-related redox stress and exercise tolerance in aged mice, Chiao et al. reported late-life restoration of mitochondrial function in old mice, and Sabbah et al. reported effects on left ventricular and mitochondrial function in a canine heart-failure model.[8][9][10]

3. KLOW (160 mg across 2 vials) — Four-Peptide Tissue-Repair Blend

Each KLOW vial contains four peptides with distinct reported targets. GHK-Cu (50 mg) coordinates Cu(II) and has been reported to modulate broad gene-expression programs and matrix proteins.[12][13][14] BPC-157 (10 mg) has been associated with VEGFR2 activation in endothelial models.[15][16] TB-500 (10 mg) carries the actin-binding motif of Thymosin β4.[17][18] KPV (10 mg) is the C-terminal α-MSH tripeptide studied for anti-inflammatory activity and PepT1-mediated uptake.[19][20]

No published pharmacokinetic, pharmacodynamic, or interaction study has evaluated retatrutide, SS-31, and the KLOW peptides administered together. Any combined behaviour is unstudied.

Research Applications (Component-Level)

The published work behind each vial in this kit falls into the following areas. Every study listed used a single component, not the stack.

1. Incretin and glucagon receptor pharmacology — retatrutide is the triple-agonist reference compound used to separate the contribution of glucagon-receptor engagement from GIP/GLP-1 agonism.[1][2]
2. Metabolic and hepatic research — phase 2 trials of the pharmaceutical formulation have been published in obesity and type 2 diabetes.[3][4]
3. Mitochondrial bioenergetics — SS-31 is used as a cardiolipin-targeting tool compound in electron-transport and ATP-synthesis studies.[5][7]
4. Cardiac and ageing models — SS-31 has been evaluated in canine heart-failure and aged-mouse paradigms.[9][10]
5. Neurodegeneration models — Zhao et al. examined SS-31 in an Alzheimer's disease model.[11]
6. Tissue-repair and matrix models — the KLOW component peptides have been studied individually in wound-healing, angiogenesis, and matrix-remodeling systems.[12][15][18]
7. Inflammation models — KPV has been examined in murine colitis and inflammatory bowel disease models.[20]

Important: no cited study used the combined stack. Researchers should not assume that single-agent findings carry over to co-administration.

Research Summary (Component-Level)

No peer-reviewed study has evaluated this five-vial stack as a unit. The table below lists representative findings for each component individually. Full per-component data and complete reference lists are on the dedicated GLP3-R, SS-31, and KLOW pages.